Evidence map›Paper›PMID 21778151›Full record

Trial reportNicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco2012

Varenicline versus bupropion XL for smoking cessation in older adolescents: a randomized, double-blind pilot trial.

Kevin M Gray, Matthew J Carpenter, A Lee Lewis, Erin M Klintworth, Himanshu P Upadhyaya

Open access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 5 pooled it
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 5 syntheses or guidelines pooled it, 52 citations in OpenAlex.

  1. Nicotine receptor partial agonists for smoking cessation.The Cochrane database of systematic reviews · 2023
    Pooled it
  2. Antidepressants for smoking cessation.The Cochrane database of systematic reviews · 2020
    Pooled it
  3. Tobacco cessation interventions for young people.The Cochrane database of systematic reviews · 2017
    Pooled it
  4. Nicotine receptor partial agonists for smoking cessation.The Cochrane database of systematic reviews · 2016
    Pooled it
  5. Sex Differences in Varenicline Efficacy for Smoking Cessation: A Meta-Analysis.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2016
    Pooled it
  6. Trial
  7. Trial
  8. Zonisamide Reduces Withdrawal Symptoms But Does Not Enhance Varenicline-Induced Smoking Cessation.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2016
    Trial
  9. A double-blind placebo-controlled randomized trial of varenicline for smokeless tobacco dependence in India.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2014
    Trial
  10. Article
  11. Article
  12. Antidepressants for smoking cessation.The Cochrane database of systematic reviews · 2023
    Review
  13. Review
  14. Effects of bupropion and SSRI antidepressants on leg movement activity and chin muscle tone during sleep in adolescents.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2023
    Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Pharmacological Treatment of Youth Substance Use Disorders.Journal of child and adolescent psychopharmacology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Kevin M GrayDepartment of Psychiatry and Behavioral Sciences, Medical University of South Carolina, 67 President Street, MSC861, Charleston, SC 29425, USA. graykm@musc.edu
Matthew J Carpenter
A Lee Lewis
Erin M Klintworth
Himanshu P Upadhyaya
Medical University of South Carolina · USMUSC Hollings Cancer Center · US

Funding

AACAP Physician Scientist Program in Substance UseK12DA000357 · NIDA · AMERICAN ACADEMY-CHILD/ADOLESCENT PSYCH · PI Kevin M. Gray · 1998 to 2026
$29.1M
SOUTH CAROLINA CLINICAL & TRANSLATIONAL RESEARCH INSTITUTE (SCTR)UL1RR029882 · NCRR · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BRADY, KATHLEEN T. · 2009 to 2011
$10.1M
South Carolina Clinical & Translational Research Institute (SCTR)UL1TR000062 · NCATS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BRADY, KATHLEEN T. · 2012 to 2014
$9.4M
Drug Abuse Research Training (DART) ProgramR25DA020537 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI KATHLEEN T. BRADY, Sudie E Back · 2006 to 2026
$6.3M
Stimulus Control and Trajectories of Adolescent SmokingK23DA020482 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI CARPENTER, MATTHEW J · 2007 to 2011
$869k
NCATS NIH HHS UL1 TR000062NCRR NIH HHS UL1 RR029882NCRR NIH HHS UL1RR029882NIDA NIH HHS K12 DA000357NIDA NIH HHS K12DA000357NIDA NIH HHS K23DA020482NIDA NIH HHS R25 DA020537NIDA NIH HHS R25DA020537
6 · The paper itself

Abstract

introductionDespite tremendous potential public health impact, little work has focused on development of evidence-based smoking cessation treatments for adolescents, including pharmacotherapies. No prior studies have explored the feasibility and safety of varenicline and bupropion XL, 2 potentially promising pharmacotherapies, as smoking cessation treatments in adolescents.

methodsTreatment-seeking older adolescent smokers (ages 15-20) were randomized (double-blind) to varenicline (n = 15) or bupropion XL (n = 14), with 1-week titration and active treatment for 7 weeks. Structured safety, tolerability, and efficacy assessments (cotinine-confirmed 7-day point prevalence abstinence) were conducted weekly.

resultsThere were no serious adverse events. Two participants discontinued bupropion XL due to adverse effects, and none discontinued varenicline. Over the course of treatment, participants receiving varenicline reduced from 14.1 ± 6.3 (mean ± SD) to 0.9 ± 2.1 cigarettes/day (CPD, 4 achieved abstinence), while those receiving bupropion XL reduced from 15.8 ± 4.4 to 3.1 ± 4.0 CPD (2 achieved abstinence).

conclusionsThese preliminary results support the feasibility and safety of conducting adequately powered, placebo-controlled efficacy studies of varenicline and bupropion XL for adolescent smoking cessation.

Indexed as

AdolescentBenzazepinesBupropionDouble-Blind MethodFemaleHumansMaleNauseaPilot ProjectsQuinoxalinesSleep Initiation and Maintenance DisordersSmokingSmoking CessationTobacco Use Cessation DevicesTreatment OutcomeVareniclineBenzazepinesBupropionQuinoxalinesVarenicline

Identifiers

PMID21778151
PMCPMC3265741
OpenAlexW2048169408

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.